Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis
- PMID: 20211896
- PMCID: PMC2863633
- DOI: 10.1128/AAC.01691-09
Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis
Abstract
Isoniazid (INH) is an effective first-line antituberculosis drug. KatG, a catalase-peroxidase, converts INH to an active form in Mycobacterium tuberculosis, and katG mutations are major causes of INH resistance. In the present study, we sequenced katG of 108 INH-resistant M. tuberculosis clinical isolates. Consequently, 9 novel KatG mutants with a single-amino-acid substitution were found. All of these mutants had significantly lower INH oxidase activities than the wild type, and each mutant showed various levels of activity. Isolates having mutations with relatively low activities showed high-level INH resistance. On the basis of our results and known mutations associated with INH resistance, we developed a new hybridization-based line probe assay for rapid detection of INH-resistant M. tuberculosis isolates.
Figures


Similar articles
-
The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan.J Microbiol Immunol Infect. 2015 Jun;48(3):249-55. doi: 10.1016/j.jmii.2013.08.018. Epub 2013 Nov 1. J Microbiol Immunol Infect. 2015. PMID: 24184004
-
Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.Tuberculosis (Edinb). 2016 Sep;100:15-24. doi: 10.1016/j.tube.2016.06.002. Epub 2016 Jun 16. Tuberculosis (Edinb). 2016. PMID: 27553406
-
Mutation of katG in a clinical isolate of Mycobacterium tuberculosis: effects on catalase-peroxidase for isoniazid activation.Ukr Biochem J. 2016 Sep-Oct;88(5):71-81. doi: 10.15407/ubj88.05.071. Ukr Biochem J. 2016. PMID: 29235814
-
Impact of isoniazid resistance on virulence of global and south Indian clinical isolates of Mycobacterium tuberculosis.Tuberculosis (Edinb). 2014 Dec;94(6):557-63. doi: 10.1016/j.tube.2014.08.011. Epub 2014 Sep 6. Tuberculosis (Edinb). 2014. PMID: 25270728 Review.
-
Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens.Clin Microbiol Infect. 2020 Oct;26(10):1332-1337. doi: 10.1016/j.cmi.2020.07.004. Epub 2020 Jul 9. Clin Microbiol Infect. 2020. PMID: 32653663
Cited by
-
Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.Antimicrob Agents Chemother. 2016 Jun 20;60(7):3994-4004. doi: 10.1128/AAC.00222-16. Print 2016 Jul. Antimicrob Agents Chemother. 2016. PMID: 27090176 Free PMC article.
-
Molecular Analysis of katG Encoding Catalase-Peroxidase from Clinical Isolate of Isoniazid-Resistant Mycobacterium tuberculosis.J Med Life. 2018 Apr-Jun;11(2):160-167. J Med Life. 2018. PMID: 30140323 Free PMC article.
-
Drug Susceptibility and Mutation Profiles in Mycobacterium tuberculosis Isolates from a Tertiary Care Hospital in Kerala, India.Am J Trop Med Hyg. 2024 May 21;111(1):161-167. doi: 10.4269/ajtmh.24-0042. Print 2024 Jul 3. Am J Trop Med Hyg. 2024. PMID: 38772358 Free PMC article.
-
Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy.mBio. 2018 May 29;9(3):e00938-18. doi: 10.1128/mBio.00938-18. mBio. 2018. PMID: 29844114 Free PMC article.
-
Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis.PLoS One. 2014 Jan 22;9(1):e86316. doi: 10.1371/journal.pone.0086316. eCollection 2014. PLoS One. 2014. PMID: 24466020 Free PMC article.
References
-
- Aristimuno, L., R. Armengol, A. Cebollada, M. Espana, A. Guilarte, C. Lafoz, M. A. Lezcano, M. J. Revillo, C. Martin, C. Ramirez, N. Rastogi, J. Rojas, A. V. de Salas, C. Sola, and S. Samper. 2006. Molecular characterisation of Mycobacterium tuberculosis isolates in the First National Survey of Anti-tuberculosis Drug Resistance from Venezuela. BMC Microbiol. 6:90. - PMC - PubMed
-
- Aziz, M., A. Laszlo, M. Raviglione, H. Rieder, M. Espinal, and A. Wright. 2003. Guidelines for surveillance of drug resistance in tuberculosis, Second edition ed. World Health Organization, Geneva, Switzerland.
-
- Bernstein, J., W. A. Lott, B. A. Steinberg, and H. L. Yale. 1952. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am. Rev. Tuberc. 65:357-364. - PubMed
-
- Bertrand, T., N. A. Eady, J. N. Jones, Jesmin, J. M. Nagy, B. Jamart-Gregoire, E. L. Raven, and K. A. Brown. 2004. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J. Biol. Chem. 279:38991-38999. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources